Podcasts about Idiopathic pulmonary fibrosis

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for October 5-11, 2025: 1. FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 Years The FDA approved roflumilast cream 0.05% for mild to moderate atopic dermatitis in children aged 2–5 years, expanding Arcutis' roflumilast portfolio. 2. Nerandomilast Nets First New FDA Approval for Idiopathic Pulmonary Fibrosis in Over 10 Years Nerandomilast became the first newly approved therapy for idiopathic pulmonary fibrosis in over a decade, offering a well-tolerated option that slows lung function decline. 3. LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Long-term data confirmed mirikizumab provides durable clinical, endoscopic, and quality-of-life benefits for ulcerative colitis up to four years, even in patients who failed prior advanced therapy. 4. Bax24: Baxdrostat Achieves Primary Endpoint in Treatment-Resistant Hypertension Baxdrostat met its primary endpoint in a phase 3 trial for treatment-resistant hypertension, supporting its potential role as a new option for difficult-to-control blood pressure. 5. Topical Bimiralisib Shows 92% Clearance Rate for Patients with Actinic Keratosis  Phase 2 data showed topical bimiralisib achieved high lesion clearance with favorable tolerability in patients with actinic keratosis.

Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

BUFFALO, NY — September 11, 2025 — A new #research paper was #published in Volume 17, Issue 8 of Aging-US on August 8, 2025, titled “AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging.” In this study, researchers Fedor Galkin, Shan Chen, Alex Aliper, Alex Zhavoronkov, and Feng Ren from Insilico Medicine used artificial intelligence (AI) to investigate the similarities between idiopathic pulmonary fibrosis (IPF), a severe lung disease, and the aging process. Their findings show that IPF is not simply accelerated aging, but a distinct biological condition shaped by age-related dysfunction. This insight may lead to a new approach in how scientists and clinicians treat this complex disease. IPF mainly affects individuals over the age of 60. It causes scarring of lung tissue, making it harder to breathe and often leading to respiratory failure. Current treatments can slow the disease but rarely stop or reverse its progression. The researchers used AI to identify shared biological features between aging and fibrosis, finding new potential targets for therapy. The team developed a “proteomic aging clock” based on protein data from more than 55,000 participants in the UK Biobank. This AI-driven tool accurately measured biological age and found that patients with severe COVID-19, who are at increased risk for lung fibrosis, also showed signs of accelerated aging. This suggests that fibrosis leaves a detectable biological trace, supporting the use of aging clocks in studying age-related diseases. “For aging clock training, we used the UK Biobank collection of 55319 proteomic Olink NPX profiles annotated with age and gender.” They also developed a custom AI model, ipf-P3GPT, to compare gene activity in aging lungs versus those with IPF. Although some genes were active in both, many showed opposite behavior. In fact, more than half of the shared genes had inverse effects. This means IPF does not just speed up aging but also disrupts the body's normal aging pathways. The study identified unique molecular signatures that distinguish IPF from normal aging. While both involve inflammation and tissue remodeling, IPF drives more damaging changes to lung structure and repair systems. This difference could guide the development of drugs that specifically target fibrosis without affecting normal aging. By combining AI with large-scale biological data, the study also introduces a powerful toolset for examining other age-related conditions such as liver and kidney fibrosis. These models may support personalized treatments and expand understanding of the relationships between aging and disease, opening new directions for therapy development. DOI - https://doi.org/10.18632/aging.206295 Corresponding author - Alex Zhavoronkov - alex@insilico.com Abstract video - https://www.youtube.com/watch?v=24lX2lHbt7o Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206295 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, IPF, generative AI, transformer, proteomics To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY — September 4, 2025 — A new #research perspective was #published in Volume 17, Issue 8 of Aging (Aging-US) on August 16, 2025, titled “Age-related diseases as a testbed for anti-aging therapeutics: the case of idiopathic pulmonary fibrosis.” In this research perspective, Alex Zhavoronkov, Dominika Wilczok, Feng Ren, and Fedor Galkin, from Insilico Medicine, Buck Institute for Research on Aging, and Duke University, propose a new method to evaluate age-related diseases based on how closely they align with the biological processes of aging. Their analysis shows that idiopathic pulmonary fibrosis (IPF), a progressive lung condition, is one of the diseases most strongly associated with aging. This makes IPF a promising model for testing new anti-aging therapies with the potential to treat multiple age-related conditions. “This perspective explores how aging-related diseases (ARDs) can serve as experimental platforms for discovering new geroprotective interventions.” While many age-related diseases are used as models for aging research, not all accurately reflect the biology of aging. To address this, the authors developed a scoring system that measures how closely a disease is connected to the key hallmarks of aging, such as inflammation, genetic instability, and impaired cellular repair. Using this system, they evaluated 13 common age-related diseases and found that IPF had a particularly high overlap with aging biology. IPF is a chronic disease that causes scarring in the lungs and a rapid decline in lung function. In contrast to the gradual loss of function seen in normal aging, IPF progresses more than five times faster. The authors highlight that IPF shares nearly all of the biological features associated with aging. These similarities make IPF a strong candidate for studying aging and testing therapies that target its underlying causes. The authors also discuss different therapies currently being developed for IPF that are also designed to address aging itself. These include drugs that clear senescent cells, activate telomerase to maintain chromosome health, or repair damaged signaling between cells. Some of these treatments, such as senolytic combinations and AI-discovered compounds like rentosertib, are already showing early promise in preclinical or clinical trials. In addition, the authors point out that IPF's fast progression and clearly measurable outcomes offer an advantage for clinical testing. If a therapy proves effective in IPF, it may also be useful for other conditions that share similar aging-related mechanisms, including diabetes, arthritis, and heart disease. This approach could accelerate drug development and reduce costs by focusing on therapies that target shared biological pathways. Overall, this perspective supports a shift in pharmaceutical research toward treating aging as an underlying cause of many chronic diseases. By positioning IPF as a model for aging-related drug development, the authors propose a strategic pathway for testing and expanding anti-aging therapies across a wide range of health conditions. DOI - https://doi.org/10.18632/aging.206301 Corresponding author - Alex Zhavoronkov – alex@insilico.com Video short - https://www.youtube.com/watch?v=p5ur7itzvSI Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this episode, host Saranya Ravindran is joined by Toby Maher to explore the often-overlooked world of interstitial lung diseases. From clarifying common misconceptions to highlighting AI innovations and personalised treatments, the series dives deep into what clinicians need to know about these serious lung conditions. Whether you're new to interstitial lung diseases or experienced in respiratory care, this series offers timely insights and expert takeaways. Timestamps: 00:00: Introduction 00:40: Mainstays of treatment 04:42: Limitations of current antifibrotics 07:50: The future of ILD personalised care 13:40: Are we close to the reversal of fibrosis? 15:52: A message for clinicians

In this episode, host Saranya Ravindran is joined by Toby Maher to explore the often-overlooked world of interstitial lung diseases. From clarifying common misconceptions to highlighting AI innovations and personalised treatments, the series dives deep into what clinicians need to know about these serious lung conditions. Whether you're new to interstitial lung diseases or experienced in respiratory care, this series offers timely insights and expert takeaways. Timestamps: 00:00: Introduction 00:41: Challenges in early diagnosis 03:22: ILD biomarkers 05:49: The overlap with autoimmune diseases 09:16: AI in ILD detection

In this episode, host Saranya Ravindran is joined by Toby Maher to explore the often-overlooked world of interstitial lung diseases. From clarifying common misconceptions to highlighting AI innovations and personalised treatments, the series dives deep into what clinicians need to know about these serious lung conditions. Whether you're new to interstitial lung diseases or experienced in respiratory care, this series offers timely insights and expert takeaways.

In this episode, host Saranya Ravindran is joined by Toby Maher to explore the often-overlooked world of interstitial lung diseases. From clarifying common misconceptions to highlighting AI innovations and personalised treatments, the series dives deep into what clinicians need to know about these serious lung conditions. Whether you're new to interstitial lung diseases or experienced in respiratory care, this series offers timely insights and expert takeaways. Timestamps: 00:00: Introduction 02:00: ILD landscape: UK versus USA 04:33: What falls under the ILD umbrella? 06:38: Idiopathic pulmonary fibrosis 07:58: Understanding different patient profiles 09:28: Early clinical signs of ILD

MaryLuz Fuentes, MD, a former clinician and double-lung transplant survivor will typically say this to other IPF patients: "We patients may be short of breath, but not short of hope." On this episode with host Patti Tripathi, Dr. Fuentes talks about what led up to her double-lung transplant three years ago and what's in store for her at the ATS 2025 International Conference in May. 

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Our episode today is diving into a broader initiative to discuss the management of interstitial lung disease. In this episode we will be talking about the treatment of Idiopathic Pulmonary Fibrosis through the lens of a journal club discussion of … Continue reading →

Today's guest is Terri Pilawa. Terri started feeling ill in 2008 and was finally diagnosed correctly after 4 years of not knowing what was wrong in 2012 with Idiopathic Pulmonary Fibrosis. She was told she needed a lung transplant. In 2015, she had a successful double lung transplant. As a part of her journey she became involved with the One Breath Foundation and is now the CEO. Let's hear about both her IPF journey and her involvement in the One Breath Foundation.

Idiopathic Pulmonary Fibrosis (IPF) is a devastating lung disease affecting millions worldwide, with a grim prognosis of only three to five years post-diagnosis. In this episode, leading lung disease expert Victor Thannickal, MD, delves into the symptoms, progression, and impacts of IPF. He also sheds light on promising new drug therapies emerging from his lab, offering hope in the fight against this relentless disease. Host Elaine Hamm, PhD, skillfully navigates the complex landscape of IPF, making this a must-listen for anyone interested in cutting-edge biotech developments. If you enjoyed the episode, please consider liking, sharing, and subscribing to BIO from the BAYOU. Your support helps us continue delivering high-quality content to listeners passionate about the biotech industry.

Host: Jonathan Chung, MD Host: Seth Kligerman, MD Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach.

CME credits: 1.00 Valid until: 07-11-2024 Claim your CME credit at https://reachmd.com/programs/clinicians-roundtable/idiopathic-pulmonary-fibrosis-the-role-of-radiology-in-accurate-and-timely-diagnosis/18077/ Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach. =

Dr. Sunad Rangarajan chats with Dr. Corrine Kliment about her article, "Loss of ANT1 Increases Fibrosis and Epithelial Cell Senescence in Idiopathic Pulmonary Fibrosis." 

Join us on a remarkable journey with Alastair Henry, the adventurous boomer and double lung transplant survivor who turned his life around post-retirement. From the corporate boardrooms to the remote Canadian North, to volunteering across the globe, Alastair's story is a testament to living life to the fullest. Discover how he embraced indigenous wisdom, tackled idiopathic pulmonary fibrosis, and found joy in simplicity on this inspiring episode of the Living the Dream podcast with Curveball.

Dr. Mohleen Kang chats with Dr. Aparna Swaminathan and Dr. Timothy Dempsey about their articles, "External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources” and “The Added Power of Synthetic Control Groups: Challenging Conventional Wisdom and Trial Design in Idiopathic Pulmonary Fibrosis Research.” 

The publication of this podcast was funded by CSL Behring. The views and opinions expressed are exclusively those of the speakers.   In this section, the panel considers the expert insights of Prof. Wijsenbeek, concerning the challenges of predicting the disease course and prognosis of patients with idiopathic pulmonary fibrosis (IPF). The conversation reflects on current knowledge, real-world practices, treatment options, and tools available to healthcare professionals.

The publication of this podcast was funded by CSL Behring. The views and opinions expressed are exclusively those of the speakers. In this section, the panel considers the diagnostic tools and approaches available for healthcare professionals to use for suspected idiopathic pulmonary fibrosis (IPF). The discussion is directed towards the expertise of Prof. Luca Richeldi, who emphasises the importance of knowledge, education, and medical examination approaches for addressing the unmet medical needs associated with the awareness of, and diagnostic delays of IPF.

Idiopathic Pulmonary Fibrosis, or IPF, is a progressive lung disease with genetic and environmental causes, affecting 5 million people globally. Although pollutants have long been linked to a range of lung diseases,  no conclusive evidence regarding their link to IPF has been sought thus far. The research of Dr. Eun Joo Kim, a post-doctorate researcher at The University of Colorado Anschutz Medical Campus, defines the role of cilia in lung repair following injury, and details how cilia related genes may be responsible for the severity of symptoms.Read the original article: https://doi.org/10.1165/rcmb.2021-0554OC

Ben Verlander welcomes New York Yankees legend Bernie Williams back to the show. They discuss the current state of the New York Yankees, what it meant to have his number retired and what advice he would give Shohei Ohtani during free agency. They also talk about his favorite Derek Jeter story, what he sees in Yankees' Jasson Dominguez and his thoughts on New York Mets new manager Carlos Mendoza. Bernie also talks about National Caregivers Month, his father's battle with Idiopathic Pulmonary Fibrosis (or IPF) and his work with Boehringer Ingleheim & the Tune In To Lung Health Program. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast, Drs Jeffrey Swigris and Toby Maher discuss the future of idiopathic pulmonary fibrosis. Find out where we're headed regarding diagnostic and treatment innovations on the near horizon. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982426). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Idiopathic Pulmonary Fibrosis: Present Understanding and Future Options https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584113/ Predicting Prognosis in Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/21319590/ Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/35569036/ Inhaled Treprostinil and Forced Vital Capacity in Patients With Interstitial Lung Disease and Associated Pulmonary Hypertension: A Post-hoc Analysis of the INCREASE Study https://pubmed.ncbi.nlm.nih.gov/34214475/ Pulmonary Fibrosis Foundation https://www.pulmonaryfibrosis.org/ Predictors of Progression in Systemic Sclerosis Patients With Interstitial Lung Disease https://pubmed.ncbi.nlm.nih.gov/32079645/

In this special episode Liz tells us about her experience of living with RA-ILD, which is short for rheumatoid arthritis-associated interstitial lung disease. We explore the profound impact of this life-changing diagnosis on Liz and her loved ones as well as the need for increased awareness of the condition. Throughout Liz provides advice and strategies for maintaining a positive outlook despite the challenges RA-ILD presents.

This episode covers interstitial lung disease, including idiopathic pulmonary fibrosis.Written notes can be found at https://zerotofinals.com/medicine/respiratory/interstitiallungdisease/ or in the respiratory section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.

Dr Jeffrey J. Swigris and Professor Anne Holland discuss the finer points of oxygen therapy for patients with idiopathic pulmonary fibrosis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982425). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Home Oxygen Therapy for Adults With Chronic Lung Disease: An Official ATS Clinical Practice Guideline Implementation Tools https://www.thoracic.org/statements/guideline-implementation-tools/home-oxygen-therapy-for-adults.php The King's Brief Interstitial Lung Disease (KBILD) Questionnaire: An Updated Minimal Clinically Important Difference https://bmjopenrespres.bmj.com/content/6/1/e000363 Ambulatory Oxygen for Treatment of Exertional Hypoxaemia in Pulmonary Fibrosis (PFOX Trial): A Randomised Controlled Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737108/

In this episode, we explore how innovating today could have a positive impact on those diagnosed with pulmonary fibrosis. We are joined by extraordinary guests, including researchers, healthcare providers, innovators, and a patient impacted by this rare disease. Keeping patients' lived experiences front and center can help lead to new ideas and progress, all while inspiring us to remain hopeful for the future.

Editor's Summary by Anne Rentoumis Cappola, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the May 9, 2023, issue. Related Content: Audio Highlights

KSQD 5-06-2023: Advances in anti-aging drugs; A survey of many brain-computer interface devices available and being developed

Drs Jeffrey Swigris and Marlies Wijsenbeek discuss how to best manage care for patients with idiopathic pulmonary fibrosis using remote monitoring to address quality-of-life concerns. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982423). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Remote Monitoring in Idiopathic Pulmonary Fibrosis: Home Is Where the Bluetooth-Enabled Spirometer Is https://www.atsjournals.org/doi/full/10.1164/rccm.202005-1532ED Challenges in Pulmonary Fibrosis – 1: Use of High Resolution CT Scanning of the Lung for the Evaluation of Patients With Idiopathic Interstitial Pneumonias https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117220/ Spirometry: Step by Step https://breathe.ersjournals.com/content/8/3/232

Drs Jeffrey Swigris and Ayodeji Adegunsoye discuss fibrosing interstitial lung disease and treatment challenges for individuals with idiopathic pulmonary fibrosis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982422). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Idiopathic Pulmonary Fibrosis (An Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline https://pubmed.ncbi.nlm.nih.gov/35486072/ Health-Related Quality of Life and Symptoms in Patients With IPF Treated With Nintedanib: Analyses of Patient-Reported Outcomes From the INPULSIS® Trials https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990488/ Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Clinical Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089322/

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease that leads to progressive lung scaring and eventual respiratory failure; it most often affects the elderly. The American Thoracic Society and other international bodies updated clinical practice guidelines for this disease in 2022. Tracy Luckhardt, MD, a pulmonologist, summarizes the most important changes to diagnosis, pharmacological treatments, and non-pharmacological treatments. Learn more about the advantages of an interdisciplinary team in managing symptoms and comorbidities of IPF, including determining when a patient is a good candidate for clinical trials or a lung transplant.

Eric LeFebvre, MD, Chief Medical Officer at Pliant Therapeutics, discusses positive safety and efficacy data from the phase 2a INTEGRIS-IPF clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF).IPF is a chronic, progressive, fibrosing lung disease with few treatment options and a poor prognosis. Common symptoms of IPF include shortness of breath and difficulty performing daily activities, such as walking and talking. Currently, there is no pharmacological cure for IPF with neither of the approved two therapies demonstrating an ability to stop the progression of the disease.

Idiopathic pulmonary fibrosis (IPF) is one of the common forms of interstitial lung disease (those that affect the tissues between airways); it results in scarring and fibroblasts. Early diagnosis is critical to the management of this dangerous condition. Carla Copeland, MD, explains the challenge of diagnosing IPF due to its generic symptoms, which usually indicate more common breathing issues. She discusses recent innovations in how CT scans are categorized to better diagnose IPF and to help recommend patients for biopsies. Learn why Dr. Copeland works with a multidisciplinary discussion team (MDT) to diagnose this condition accurately and to begin treatment as soon as possible.

In the fifth and final episode of season 3, we learn about the impact that pulmonary fibrosis can have on relationships with family and friends, and even on the more intimate aspects of partner relationships. Our contributors also take time to emphasize the value that they derive from healthy and supportive relationships when living with this challenging condition.

2.12 Idiopathic Pulmonary Fibrosis   Pulmonary system review for the USMLE Step 1 exam.

In the second episode of Season 3 of our Journey Through Pulmonary Fibrosis podcast, we are once again joined by several people who live with the condition, including a wife and care partner, and by a group of specialists. Hear about some of the challenges that people with pulmonary fibrosis face in terms of meeting their dietary and nutritional needs and learn about how these challenges are best managed through tools and techniques like keeping a food diary and managing portion sizes.

What is an acute exacerbation? Are there different types of exacerbation related to Idiopathic Pulmonary Fibrosis? Dr. Nathaniel Marchetti of Temple Lung Center joins host Kevin Crockett to discuss acute exacerbation and more! Brought to you by the Wescoe Foundation for Pulmonary Fibrosis and the Pennsylvania IPF Support Network!! Find the 'PULMONARY FIBROSIS' podcast on Google, Spotify, Apple podcasts - wherever you get your podcasts - or at PAIPFSupportNetwork.org!!See omnystudio.com/listener for privacy information.

In the first episode of Season 3, we are joined by a courageous group of guests that includes people living with pulmonary fibrosis, a care partner, and specialized healthcare providers to explore the mental health impact of the disease. The discussion explores the impact of receiving a pulmonary fibrosis diagnosis and the ongoing challenges of living with the disease. Our guests share the mental and emotional challenges they face, as well as helpful tips on how to cope, where to find support and how they continue to find hope.

Idiopathic Pulmonary Fibrosis with Dr Horne by Dr. Laura Caputo

Moderators Aravind M Menon, MD, MPH, and Alice Gallo de Moraes, MD, and journal CHEST® author Sahajal Dhooria, MD, DM, discuss the article, "MUC5B Promoter Polymorphism and Survival in Indian Patients With Idiopathic Pulmonary Fibrosis," which was published in the October issue. DOI: https://doi.org/10.1016/j.chest.2022.04.001

Today's Episode Dr. Raj and Dr. Eva Khondaker review the case of a 68 year old man who presents to the outpatient clinic after 6 months of progressive exertional dyspnea and a persistent dry cough. He has a 15 pack year history of smoking but quit 20 years ago, and he has no family history of lung disease. Today's Guest Dr. Eva Khondaker is a recent medical graduate from the University of Medicine and Health Sciences (UMHS) where she graduated with highest honors. She holds a Bachelor of Science Degree from the University of Alberta majoring in Biological Sciences and a Minor in Classics. Eva has over 10 years of media and broadcasting experience. Her experience ranges from appearing in local news channels to International Tv networks such as ATN (Asian television network). Eva was crowned Miss Canada Galaxy International 2007, Miss Alberta 2007 and Miss Supermodel South Asia 2006. She also went on to represent Canada at an International platform and placed 1st runner up and awarded best in swimsuit and interview. She was also awarded 1st runner up in Miss India Canada 2007 in Toronto, Ontario. In the past, Eva has been an ambassador for various charity organization such as the Canadian Red cross and the Cross cancer institute to name a few. She has helped raise awareness and funding for research. Eva is also a published co-author of a Medical Ethics and Biostatistics textbook specifically for students preparing for the USMLE exams. Recently, Eva has joined inside the boards as a podcast host, tutor, question writer, and head of social media development. In her personal life, she is a trained kathak and bharatnatyam dancer (Classical East Indian dance). She loves going to the gym and all things scifi/fantasy related. In her spare time she enjoys spending time with her dog son, Quincy! She loves to go for hikes and play fetch with Quincy. She is currently preparing for the 2023 Match cycle. About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj www.BeyondThePearls.net The Dr. Raj Podcast Dr. Raj on Twitter Dr. Raj on Instagram Want more board review content? Crush Step 1 Step 2 Secrets Physiology by Physeo Step 1 Success Stories The InsideTheBoards Study Smarter Podcast The InsideTheBoards Podcast Study on the go for free! Download the Audio QBank by InsideTheBoards for free on iOS or Android. If you want to upgrade, you can save money on a premium subscription by customizing your plan until your test date on our website! Produced by Ars Longa Media To learn more about us and this podcast, visit arslonga.media. You can leave feedback or suggestions at arslonga.media/contact or by emailing info@arslonga.media. Produced by: Christopher Breitigan Executive Producer: Patrick C. Beeman, MD Legal Stuff InsideTheBoards is not affiliated with the NBME, USMLE, COMLEX, or any professional licensing body. InsideTheBoards and its partners fully adhere to the policies on irregular conduct outlined by the aforementioned credentialing bodies. The information presented in this podcast is intended for educational purposes only and should not be construed as professional or medical advice. Learn more about your ad choices. Visit megaphone.fm/adchoices

Are you or someone you know living with Idiopathic Pulmonary Fibrosis?! We have got a GREAT episode this time around with excellent information on the patient and caregiver experience from a patient living with IPF. Jim Carns joins Crockett to tell us about the patient experience of living with IPF, and about lung transplants. It's the 'PULMONARY FIBROSIS' podcast! Brought to you by the Wescoe Foundation for Pulmonary Fibrosis, and the PAIPF Support Network! Learn more at PAIPFSUPPORTNETWORK.org!!See omnystudio.com/listener for privacy information.

How does dapagliflozin affect kidney outcomes in patients hospitalized with COVID-19? Find out about this and more in today's PV Roundup podcast.

What a first year it has been! We've gotten to know SO MUCH about Idiopathic Pulmonary Fibrosis, and this whole idea for an informational podcast started with Jen Wescoe of the Wescoe Foundation for Pulmonary Fibrosis! She tells us about what exciting things we can expect from the show in 2022 in this episode of the PULMONARY FIBROSIS PODCAST! Brought to you by the the Pennsylvania IPF Support Network and the Wescoe Foundation for Pulmonary Fibrosis! Find the 'Pulmonary Fibrosis' podcast on Spotify, Apple Podcasts or wherever you get your podcasts - and learn more at paipfsupportnetwork.org!!See omnystudio.com/listener for privacy information.

We are joined by John who spent a decade seeking a correct diagnosis of the rare lung disease, Idiopathic Pulmonary Fibrosis. Listen to him explain the importance of sharing symptoms with your doctor and how he considers his eventual diagnosis to be the beginning of a new journey.